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Abstract 
Aberrant hypermethylation of CpG islands (CGI) in human tumors occurs predominantly at repressed genes in 
the host tissue, but the preceding events driving this phenomenon are poorly understood. In this study, we 
temporally tracked epigenetic and transcriptomic perturbations which occur in a mouse model of liver 
carcinogenesis. Hypermethylated CGI events in the model were predicted by enrichment of the DNA 
modification 5-hydroxymethylcytosine (5hmC) and the histone H3 modification H3K27me3 at silenced 
promoters in the host tissue. During cancer progression, CGI underwent hypo-hydroxymethylation prior to 
hypermethylation, whilst retaining H3K27me3. In livers from mice deficient in Tet1, a tumor suppressor 
involved in cytosine demethylation, we observed a similar loss of promoter core 5hmC, suggesting that 
reduced Tet1 activity at CGI may contribute to epigenetic dysregulation observed during 
hepatocarcinogenesis. Consistent with this possibility, mouse liver tumors exhibited reduced Tet1 protein 
levels. Similar to humans, DNA methylation changes at CGI in mice did not appear to be direct drivers of 
hepatocellular carcinoma progression, rather, dynamic changes in H3K27me3 promoter deposition correlated 
strongly with tumor-specific activation and repression of transcription. Overall, our results suggest that loss of 
promoter-associated 5hmC in liver tumors licenses reprogramming of DNA methylation at silent CGI during 
progression. 
 
Introduction 
Significant advances have been made in the study of epigenetic reprogramming associated with specific cancer 
and tumour subtypes(1). Much t of the focus has been on DNA methylation reprogramming or alterations in 
the post translation modifications (PTM) of DNA bound histone proteins such as tri-methylation at lysine 27 on 
Histone H3 (H3K27me3)(2,3). The identification of several new forms of modified cytosine in vertebrate DNA 
has added to this narrative by providing new patterns for interpretation, hypothesis building and functional 
outcomes (4). In particular, 5-hydroxymethlycytosine (5hmC), generated from a 5–methylcytosine (5mC) 
precursor by the Ten-Eleven-Translocation (TET) enzymes, is hypothesised to be part of a predicted 
demethylation pathway and that differs significantly in its genomic distributions from that of 5mC (5-8). Whilst 
5mC tends to be found over heterochromatic and repetitive portions of the genome and has known roles in 
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the maintenance of transcriptional silencing, 5hmC is more restricted to the bodies of expressed genes, 
enhancer elements and a cohort of promoter regions in many tissues(8-10). Aside from a predicted role as a 
demethylation intermediate, the functional significance of the 5hmC modification is still largely unknown. 
However there is evidence that the genic levels of 5hmC can correlate with the transcriptional activity of the 
associated genes in tissues whilst low-level direct enrichment of 5hmC over the core of promoters surrounding 
the transcription start site (TSS) appears to be related to transcriptional silencing events and maintenance of 
CpG hypomethylation (11-13).  
Normal 5hmC patterns are dramatically altered in several human cancer types such as melanoma and 
hepatocellular carcinoma; as well as in cultured cancer cell lines and colon cancer (9,11,14-16). In previous 
work, we have identified hypermethylation prone promoters in various human cancer types which overlap 
with Polycomb regulated gene sets (17). We speculated that these genes are prone to methylation due to their 
inactivity in cancer-host tissue and loss of a demethylase activity (2). A possibility is that 5hmC/Tet enzymes 
are involved in this process, as loss of Tet activity from such promoters may licence the occurrence of 
aberrantly hypermethylatyed CpG islands (CGI) in cancer. 
Previously we carried out a number of studies investigating the epigenetic perturbations that occur in 
liver following exposure to the well-studied rodent non-genotoxic carcinogen (NGC), Phenobarbital (PB), to 
elucidate potential drug induced epigenetic changes that anticipate cellular transformation (13,18,19). PB is an 
antiepileptic drug which promotes hepatocarcinogenesis in rodents when administered subsequent to an 
initiating carcinogen such as N-nitrosodiethylamine (DEN) (20). This results in selective clonal outgrowth of 
cells harbouring activating mutations in the proto-oncogene Ctnnb1, encoding β-Catenin, a key mediator in the 
canonical Wnt signaling pathway (21). In this study we attempt to delineate the progression of 
hepatocarcinogenesis through combined epigenetic (5mC, 5hmC & H3K27me3 patterns) and transcriptomic 
analysis... Our study tracks the initial epigenetic and transcriptomic perturbations throughout the early stages 
of toxicological insult and follows them to an ‘end-state’ that is characteristic of liver tumour formation in 
three models (21,22). As a result we link initial loss of 5hmC at CGI promoters with the occurrence of aberrant 
hypermethylated CGIs in tumours. This occurs at genes that are repressed in normal liver and remain silent in 
the resulting tumours, possibly due to the continuous presence of the inactivating mark H3K27me3.  
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Materials and Methods 
Study material and animal treatment 
For full description of mouse strains and treatment regimes, please see supplemental materials and methods.  
 
Methyl and hydroxymethyl DNA immunoprecipitation (MeDIP & hMeDIP)  
Genomic DNA was extracted from frozen ground-up samples and fragmented to a range between 300 bp to 
1,000 bp in size (Bioruptor, Diagenode) prior to immunoprecipitation with 5hmC (active motif #39769) or 5mC 
(Eurogentic # BI-MECY-1000) antibodies. For HmeDIP and MeDIP protocols see;(13,18). DNA was purified using 
DNA Clean & Concentrator™ (Zymo Research). 5hmC and 5mC patterns were then generated following dye 
labelling and hybridisation to promoter specific microarrays – either on 2.1M Deluxe mouse promoter tiling 
microarrays (Roche Nimblegen) for the control, 12 week PB, Ctnnb1 and Ha-ras tumours or on 1M mouse 
promoter microarrays (Agilent) for control and NASH hepatocellular carcinoma (HCC) tumour samples.  
 
Genome wide ChIP-sequencing of H3K27me3  
25 μg of chromatin was taken for the control liver, a 12 week PB treated liver and a PB exposed liver tumour 
and H3K27me3 chromatin immunoprecipitation carried out using 4 μg of antibody (Millipore, cat # 07-449) as 
described previously (23). Following this, Illumina libraries were prepared by Active Motif (Active Motif) and 
samples sequenced by HiSeq and mapped against the mouse reference genome (mm9 build). 
 
Preparation of RNA for strand specific RNA sequencing 
Total RNA was extracted from the 2 control livers, 2 livers of mice treated with PB for 12 weeks and 3 tumours 
which have arisen through sequential DEN/PB treatment. Strand-specific mRNA-seq libraries for the Illumina 
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platform were generated through poly-A enrichment and sequenced at BaseClear BV (BaseClear, Leiden, the 
Netherlands). For full methods see supplemental information.  
 
Data Access 
All data for this study can be found at the Gene Expression Omnibus (GEO) in the super series GSE77731. 
Published mouse liver 5hmC datasets were analyzed from GEO series GSE40540 (13,19). Published fetal liver 
RNAseq data analyzed from GEO samples GSM850909. Mouse embryonic stem cell TET1 genome wide 
datasets were analyzed from GEO sample GSM611192 .  
 
Results 
5-methylcytosine and 5-hydroxymethylcytosine patterns are decoupled during hepatocarcinogenesis 
progression 
As PB is thought to promote carcinogenesis through non-genotoxic mechanisms, epigenetic reprogramming 
through long term exposure are likely to be an important indicator of liver tumour formation. Our work has 
shown that mice exposed to tumour promoting doses of PB exhibit changes to both their 5hmC and 5mC liver 
patterns at the promoter proximal regions of many genes (13,18,19). Here we expand upon these findings to 
investigate perturbations arising in hepatocellular tumours generated by a DEN/PB regimen (Supplementary 
Fig. S1A).   
Immunohistological staining of sections of mouse liver, following DEN/PB exposure, with antibodies 
against glutamine synthetase (GS) identify Ctnnb1-mutated hepatocellular tumour-lesions which are 
dependent on an activated Wnt/β-catenin signalling pathway (Fig. 1A) (24). Staining with antibodies against 
5mC or 5hmC reveals that these Ctnnb1-mutated tumours have reduced signals for both DNA modifications 
(Fig. 1A), an observation also reported in several types of human cancer including HCC (16). DNA modification 
patterns were directly investigated by immunoprecipitation with specific antibodies towards either 5hmC or 
5mC prior to hybridization on high density promoter microarrays with a set of control mouse liver DNAs (n=2) 
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and liver DNAs from mice that had been exposed to phenobarbital in their drinking water for 12 weeks (n=2) 
or in the excised hepatic tumours from mice which had received PB for 35 weeks (n=3). Analysis of overall 
Pearson’s correlation scores between the samples reveals that the 5hmC pattern is strongly perturbed 
following drug dosing (and in the tumours), whilst 5mC patterns are largely similar following drug dosing but 
differ greatly in the tumour samples (Fig. 1B). This result suggests that a change in 5hmC profiles might 
precede that of 5mC. 
Next we defined differentially hydroxymethylated regions (dHMRs) or differentially methylated 
regions (dMRs) between the control and PB exposed livers or between the control and tumour samples 
(Supplementary Fig. S1B). Mapping of the resulting dHMRs and dMRs to one of five genomic compartments 
(inter-genic, promoter distal, promoter proximal, promoter core or intra-genic; Supplementary Fig. S1B) 
reveals that genomic regions of epigenetic perturbation are largely distinct for the two modifications. 
Following PB exposure both at 12 weeks and in the resulting liver tumours, 5hmC was strongly lost over the 
promoter proximal and core regions and both reduced and elevated in the bodies of genes (Supplementary 
Fig. S1B). In contrast, an increased number of 5mC peaks were observed in the tumour samples compared to 
those exposed to short term PB. Additionally, although 5mC was seen to be both acquired and lost at 
intergenic and intragenic loci following 12 week PB exposure, hypo-methylation was typically observed at such 
sites in the resulting tumours. 
 
Tumour specific promoter hyper-methylation occurs after phenobarbital mediated loss of 5hmC   
As the 5hmC modified DNA is itself derived from TET oxidised hydroxylation of a 5mC precursor, we set out to 
test the relative changes in both marks across all of the promoters. Firstly, we identified a subset of promoter 
core regions are marked by 5hmC in the normal livers in this study (Fig. 1C). Independent validation of select 
loci by glucosylation-mediated restriction enzyme sensitive qPCR (gRES-qPCR; see supplementary experimental 
procedures) reveals that these sites contain ~15% to 20% 5hmCpG, whilst a control region of low 5hmC and 
5mC at Gapdh was only found to contain less than 5% 5hmCpG (Supplementary Figs. S2 & S3). 
Analysis of the DNA modification patterns reveal that there is a dramatic loss in promoter core 5hmC 
levels in the livers of mice exposed to PB for 12 weeks as well as in the resulting tumours (Supplementary Fig. 
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S4). In contrast, 5mC levels were unaffected following chronic PB dosing. However we observed a strong 
acquisition of 5mC at a subset of CpG islands in the tumour samples - the majority of which were initially 
marked by 5hmC in the healthy liver (Figs. 1C, 1D, Supplementary S4 & S5 and Supplementary Table S1). 
Extension of this analysis with published liver datasets from mice receiving different lengths of PB dosing 
reveals that loss of promoter core 5hmC does not occur following acute drug exposure (i.e. 1/7 days) but 
instead requires longer chronic exposure (i.e. 28days dosing; Supplementary Fig. S6)(19). A reciprocal 5hmC 
loss/5mC accumulation was also observed at a common set of promoter elements in the PB exposed tumour 
samples (n=2037), indicating that such a “switch” may be a hallmark of hepatocarcinogenesis progression (Fig. 
1E and 1F).  
 
Promoter hypo 5hmC/hyper 5mC is a common feature of mouse liver tumour types with differing activating 
mutations 
To test if the promoter core loss of 5hmC and gain of 5mC is a feature of chemical exposure or is 
instead a more general hallmark of hepatocarcinogenesis, we also profiled 5hmC and 5mC patterns in two 
mouse liver tumours of differing pathology (Supplementary Fig. S7). One was a mouse liver tumour that had 
arisen following DEN induction only, resulting in a Ha-ras mutated tumour (22). The second set of liver 
tumours resulted from an obesity based mouse model in which neonatal male mice develop multiple HCC’s 
following non-alcoholic steatohepatitis (NASH) onset (21). In both cases we observed a gain of promoter core 
5mC at loci normally marked by 5hmC in the healthy tissue (Fig 1G & Supplementary S7). The reciprocal nature 
of the changes in 5hmC/5mC persist to some degree in all of the three tumour types with a general loss of 
5hmC accompanied by a gain in 5mC (Supplementary Figs. S7 & S8). While there was a large degree of 
commonality in the promoter core spanning probes which exhibited a loss of 5hmC or gain of 5mC between 
the three tumour types, there were also a number of regions which were unique to the particular tumour type 
which may reflect stratification of particular cancer subtypes (Supplementary Fig. S9).  
 
Promoter epigenetic dysregulation events are related to only a handful of transcriptional perturbations 
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In order to test the relationship between promoter core epigenetic dysregulation and transcriptional 
perturbation during f hepatocarcinogenesis progression, we carried out RNA-sequencing on matched control 
livers (n=2), PB treated livers (n=2) and DEN/PB induced Ctnnb1 mutated liver tumour samples (n=3). Pearson 
correlation analysis and principal component analysis (PCA) reveals that the global transcriptomic patterns of 
the Ctnnb1 mutated tumours were distinct from both control and PB treated liver (Supplementary Fig. S10). 
No clear relationship was evident between changes in the epigenetic state at promoter core elements with 
expression alterations of the associated genes (Fig. 2A). This was most notable at the promoters of genes 
exhibiting no significant change in gene expression following PB exposure or in the resulting tumours (grey 
plots Fig. 2A). However there is a significant retention of 5hmC levels over the promoter cores of the genes 
that are repressed in the tumour samples (Fishers P-value 1.99E-0.7) and a reduction of 5mC levels over 
tumour induced genes (Fishers P-value 2.52E-0.15); implying that there may be a functional relationship 
between epigenetic and transcriptomic perturbations in the progression of hepatocarcinogenesis (Fig. 2B). A 
handful of genes exhibit a strong epigenetic remodelling associated with transcriptional activation , in 
particular the Cytochrome P450 genes Cyp2b10 and Cyp2c55, which in addition to being two of the most 
strongly induced genes following PB exposure undergo a strong loss of both promoter core 5hmC and 5mC 
following PB exposure (Fig. 2C). In agreement with recent research, the genes which were identified as 
containing promoter core elements which lost 5hmC and gained 5mC upon tumorigenesis correspond to low 
expressed/transcriptionally silent genes in the healthy control liver (Fig. 2D) – highlighting that aberrant 
methylation at these loci is not directly linked to a change in their transcriptional status in the tumour (17). 
 
Key signalling pathways are perturbed during hepatocarcinogenesis progression 
We next identified differentially expressed genes that arise following PB exposure (control to PB) or upon 
tumour formation (control to tumour) (>log2 2 fold change with associated unadjusted P-values <0.05). Genes 
exhibiting a change in their gene expression patterns were grouped into one of six classes (“i” to “vi", Fig. 3A 
and 3B, & Supplementary Table S2) based on their profile in control, PB treated and the tumours. Functional 
analysis of the genes in each class reveals that distinct pathways are de-regulated following PB exposure as 
well as in the PB exposed liver tumours (Fig 3. B). For example genes de-regulated exclusively in the Ctnnb1-
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mutated tumours are linked to pathways involved in production of cell adhesion molecules, diabetes, PPAR 
signalling and TGF-beta signalling pathway. As well as genes frequently mutated or transcriptionally perturbed 
in the progression of many cancers (such as the Wnt signalling protein axin1 and the cell cycle regulator ccnd1) 
(25,26). Close inspection of the data reveals strong changes in the expression of genes related to control of 
proliferation (Cdkn1a), apoptosis and DNA damage response (Trp53 & Gadd45b), as well as genes associated 
with known cancer related signalling pathways (the Tfg-α gene, the Tgf-β pathway related tumour suppressor, 
Chd1 and the Wnt signalling component, Ctnnb1 ). In addition we observe strong PB specific responses at 
select genes previously reported to exhibit transcriptional changes following toxicological challange (Gtl2, 
Prom1 & Cytochrome P450 genes) (Fig. 3C). Together this data highlights progressive transcriptomic miss-
regulation that is indicative of physiological changes and a detoxification response.  
 
We also observed specific expression of a series of genes in the tumour samples normally associated 
with fetal liver (Fig. 3D). For example α-fetoprotein 1 (Afp1) and Glypican-3 (Gpc3), as well as the hepatocyte 
nuclear factors 1a, 1b and 4a (Hnf1a, 1b & 4a), are highly expressed in the developing fetal liver compared to 
the mature adult tissue, whist there is reduced expression of albumin (Alb) and CCAAT/enhancer-binding 
protein alpha (C/EBPa), which are normally found in the adult liver (Fig. 3D). This may represent either a 
dedifferentiation of mature hepatocytes into a more fetal like state or positive selection of liver cancer stem 
cells during tumorigenesis –which would have a potential growth advantage due to their elevated proliferative 
abilities (27). Similar changes were also observed in published expression array datasets for both PB exposed 
(Ctnnb1 mutated) and non-PB exposed (Ha-ras mutated) liver tumours (Fig. 3E) (28). 
 
A unique Polycomb mediated repression signature at CGIs is established in PB exposed mouse liver tumours  
It has been widely reported that the global levels and genome wide patterns of the repressive histone 
modification, H3K27me3), as well as the enzymes responsible for its deposition, are altered in many cancer 
types including HCC (29-31). We carried out genome wide ChIP sequencing for the H3K27me3 modification to 
determine if these Polycomb mediated silencing mechanisms are also perturbed in the PB derived liver 
tumours. Peak finding analysis indicates a general elevation in the levels of H3K27me3 signals in the PB liver 
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tumours compared to control liver (94,341 200bp window regions gain H3K27me3, 31,995 windows lose 
H3K27me3 (Fig. 4A and Supplementary Fig. S11).  
 
Focussing on promoter core regions we find that these are relatively unchanged in response to PB but 
elevated in the resulting tumour (Fig. 4B). Studies suggest that promoter regions marked by H3K27me3 in 
mouse embryonic stem cells become hyper-methylated upon mammary cancer formation (32). To test this 
possibility in our mouse liver tumour we directly compared our H3K27me3 and 5hmC/5mC datasets. Plots of 
promoter core 5hmC and 5mC change against changes in the H3K27me3 signal following PB exposure reveal 
little change in the histone modification, even though 5hmC levels are lost at a number of loci (Fig. 4C). 
However, compared to the normal genomic profile there is a strong increase in the number of hyper-
H3K27me3 peaks at promoter spanning loci upon tumour progression. Interestingly a significant proportion of 
promoters acquire 5mC without a change in H3K27me3 occupancy (Fig. 4C). Interestingly we observe only a 
very modest elevation of the H3K27me3 mark at promoters following PB exposure but a strong elevation in 
signal is observed at many promoters in the resulting tumours (Fig. 4D & Supplementary Fig. S12). Promoters 
that become hyper-methylated and hypo-hydroxymethylated in the tumours do not exhibit this elevation as 
they are already strongly enriched for H3K27m3 in normal healthy livers (Figs. 4D & 4E). In agreement with the 
notion that the H3K27me3 mark is inhibitory towards transcription, analysis of the promoter regions of genes 
induced in the tumour indicates full loss of H3K27me3 is coincident with gene activation in the resulting 
tumours. Conversely the genes that become repressed in the tumour have dramatic gains of H3K27me3 over 
their promoters in the resulting tumours (Figs. 4D, 4E & Supplementary Fig. S12).   
 
To further test the chromatin landscape of this promoter set in normal control livers we analysed the 
profiles of several other commonly studied histone tail modifications using publically available mouse liver 
epigenomics datasets produced by the ENCODE project (http://www.genome.gov/encode/) (Fig. 4F). Although 
there was no observable difference, compared to the total promoter set, in the levels of Histone H3 lysine 4 
mono-methylation (H3K4me1), H3 lysine 27 acetylation (H3K27ac) or H3 lysine 36 tri-methylation (H3K36me3), 
there was an enrichment at these promoters for the typically euchromatic mark H3 lysine 4 tri-methylation 
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(H3K4me3). This suggest that a proportion of these 5hmC marked promoters are bivalent (simultaneously 
enriched for H3K4me3 and H3K27me3).Combined analysis of the promoters which lose 5hmC and gain 5mC in 
the tumours (n=2035) reveals that a strong epigenetic transition occurs during hepatocarcinogenesis at 
promoter core elements originally bivalent/5hmC marked and transcriptionally silent genes in the normal 
healthy liver, without leading to expression changes (Fig. 4G & Supplementary Figs. S13 & S14).  
 
Tet1 protein levels are reduced in mouse HCC 
In order to better understand the epigenetic dysregulation occurring during hepatocarcinogenesis we 
investigated the transcriptomic changes in a selection of key epigenetic modifying enzymes (Fig 5A). In general, 
the majority did not exhibit a strong change in gene expression (>2 fold change vs control tissue). We did, 
however, observe a strong induction of the histone H3 lysine 9 demethylase Jmjd1c and the histone 
deacetylase Hdac11 alongside a low to moderate elevation (1.5-2 fold) of several HDACs, methyl-binding 
proteins (Mbd1), Trithorax (Mll3) and polycomb group proteins (Suz12). The levels of the methyltransferases 
Dnmt-1 (1.64 FC), -3a (1.51 FC) and -3b (0.98 FC) were not significantly altered. We did not observe changes in 
levels of expression of the Tet genes (Tet1, 2 and 3) responsible for conversion of 5hmC from 5mC. This result 
was validated both by microarray and RT-qPCR; thus loss of 5hmC in mouse HCC cannot be explained by the 
mis-expression of the Tet genes (supplementary Fig. S15) (14,19,33). As levels of the Tet1 protein were 
previously shown to be reduced in human HCC, we carried out immunohistochemistry for Tet1 in mouse liver 
tumours (16)(Fig. 5B). In agreement with the results of the human study, we did observe a strong loss of Tet1 
staining in MAPK positive tumour cells. Although levels of Tet1 expression in the mouse liver are low 
(supplementary Fig. S15), this result indicates that protein levels are readily detectable in the normal healthy 
liver tissue. Published in vitro studies have shown that loss of Tet1 is coincident with loss of 5hmC from 
promoter regions (9,34,35). Moreover in human embryonic carcinoma NCCIT cells Tet1 loss was seen to 
correlates with hypermethylation of CGIs and CpG island shores (9). Interestingly analysis of Tet1 binding sites 
in published mESC data reveals an enrichment over the promoters that we identify as becoming aberrantly 
hypermethylated in mouse liver tumours (Supplementary Fig. S16). To test for the consequences resulting 
from loss of the Tet1 protein observed in the liver tumours, we profiled 5hmC levels across the promoter 
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regions in control and Tet1 KO mouse livers by hmeDIP-seq (36). This revealed that loss of Tet1 in the mouse 
liver results in a dramatic reduction of 5hmC over a large number of promoters (Fig. 5C). This was also 
observed over the promoter regions identified as becoming aberrantly methylated following a loss of 5hmC 
during tumorigenesis (Supplementary Fig. S17) – suggesting that direct reduction in Tet1 protein levels or 
inhibition of TET activity during the progression of tumorigenesis could account for a decrease of promoter 
associated 5hmC and enable subsequent gain of 5mC. 
 
Discussion 
DNA methylation reprogramming has been previously noted for a host of tumour types including HCC 
(2,14,16,37). In addition, changes to the normal 5hmC patterns have also been reported in both mouse and rat 
livers following exposure to either non-genotoxic or genotoxic agents (13,19,38). In this present study we build 
on these early observations to show for the first time in mouse models of liver cancer that early perturbations 
in the epigenetic landscape over transcriptionally silent CGIs that are marked by low levels of 5hmC and 
H3K27me3.predicate hyper-methylation that occurs in tumours. We utilised several models of rodent liver 
tumour models (PB exposed Ctnnb1 mutant tumours, DEN treated Ha-Ras mutant tumours and NAFLD driven 
tumours) to demonstrate the same observation for each. The reciprocal nature of these changes fits with the 
notion that these two modifications exist within a programmed DNA methylation/demethylation pathway that 
is mediated by Tet enzyme activity (39). A reduction of Tet1 protein levels in mouse HCC may account for the 
observed epigenetic disruption, however this occurs without obvious changes in Tet transcript levels (Figs. 1 & 
5). We propose that reduced Tet1 binding and/or activity at target CGIs may be responsible for aberrant 
epigenetic events in many cancers (Fig. 5D). Direct loss of Tet1 function in liver results in a similar dramatic 
reduction in promoter 5hmC levels (Fig. 5C). In PB exposed mice reduction of Tet1 and 5hmC levels may also 
be linked to an elevated rate of proliferation in tumour cells and altered cellular intermediary metabolism 
(28,40). Indeed it was recently shown that both Tet1 expression and global 5hmC levels are reduced in 
proliferating cells in culture as well as in rapidly proliferating hepatocytes following partial hepatectomy 
(41,42). Finally the function of the Tet enzymes may also be affected by altered metabolic programs in these 
tumours, such as changes in the levels and utilization of the Tet enzyme cofactor α-ketoglutarate (28). 
on April 12, 2016. © 2016 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 6, 2016; DOI: 10.1158/0008-5472.CAN-15-1910 
 13 
 
Emerging data suggest that the deregulation of normal Polycomb group proteins (PcG), critical 
mediators of the “silencing” chromatin modification H3K27me3, plays causative roles in oncogenesis (31,43). 
EZH2 is often highly expressed in HCC and can have important roles in tumour progression and fetal liver 
development (44). H3K27me3 profiling during mouse PB exposure implies that an “epigenetic switch” takes 
place at the promoters of genes which are linked to changes in their expression levels during 
hepatocarcinogenesis; gains in H3K27me3 are associated with repression of genes in the tumours, while loss is 
accompanied with their activation (Fig. 4D & 4E). In contrast at the promoters which exhibit aberrant hyper-
methylation/hypo-hydroxymethylation in the liver tumours, we observe a strong enrichment of H3K27me3 
levels in the healthy tissue, which is not significantly altered in the tumours (Figs. 4C, 4D & 4G). Fittingly these 
promoters tend to be associated with transcriptionally silent genes - a result which matches with observations 
in human cancers (17). These findings are also in line with recent reports in which H3K27me3 modified histone 
tails were found to be associated with 5mC marked DNA in cultured cancer cells (45,46). Our data builds on 
previous work which indicated that promoters that are marked with H3K27me3 in embryonic stem cells are 
more likely to gain DNA methylation during differentiation and carcinogenesis than those lacking H3K27me3 
(47,48). We suggest that Tet1 binding along with PRC2 components mark promoters that are destined to 
become hypermethylated in cancer, this can be inferred by the presence of 5hmC at these regions in control 
liver samples. Similar findings have been published in human cancer cell lines where promoters marked by 
H3K27me3 and H3K4me3 were initially enriched for 5hmC but lose this modification upon depletion of Tet1 by 
siRNA (9). The finding that 5hmC and H3K27me3 marked promoters mark sites which later become hyper-
methylated in the tumours supports a model in which general aberrant methylation at CGIs is not linked with 
silencing of tumour-suppressor-genes, but instead indicates a de-coupling of TET function from PRC2 
complexes at these genes. These relationships between DNA and H3K27 methylation clearly warrant more 
careful molecular examination in vivo, especially as culturing of somatic cells in vitro leads to a reduction in Tet 
levels and subsequent de novo methylation at H3K27me3 marked promoters (42).  
A recent study in human colon cancer reports that promoter proximal regions ~1kb upstream of the 
TSS marked by 5hmC in the normal colon appear to correlate to sites which is resistant to hypermethylation in 
colon cancer progression. These results contrast with both our findings and recent observations in mouse 
mammary tumours and human embryonic carcinoma cells (9,32), in which Polycomb marked promoters in the 
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normal state may become hypermethylated in the resulting cancer. This indicates that epigenetic disruption 
during cancer progression is linked to the type of cancer in question and is likely dependant on a combination 
of both TET protein miss-regulation, tissue background and genetic mutation. Further combined epigenetic 
and transcriptomic studies, particularly in cancers arising in different tissues, will be essential in order to better 
understand the precise contribution of epigenetic pathways to hepatocarcinogenesis in particular and to 
carcinogenesis in general.   
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Fig. Legends 
Fig. 1. Levels and distributions of DNA modifications are altered following PB exposure and in resulting liver 
tumours. A. Immunostaining of liver sections with glutamine synthetase (GS) reveals Ctnnb1 mutated nodules. 
5hmC and 5mC levels are reduced in the tumour relative to e surrounding regions. B. Pearson’s correlation 
clustering of datasets for 5hmC (i) and 5mC (ii) profiles. C. Heat map analysis of log2 5hmC (blue) and 5mC 
(red) signals over promoter regions (TSS +/- 2kb) ranked by tumour 5mC level (Tum 1-3, right panel). Normal 
control livers: “Cntl”, PB exposed for 12 weeks: “PB””, Ctnnb1 mutated liver tumours: “Tum”. CGIs are denoted 
by black bars in the far right plot. Average 5hmC and 5mC patterns are plotted below (solid black lines) against 
the mean signal from the control samples (dashed green line). Dashed box outlines promoters which lose 
5hmC/gain 5mC in the tumours. D. Changes in promoter core 5hmC vs 5mC are plotted for each gene 
promoter between replicate control livers (i), between average control : 12 week PB treated livers (ii) and 
between average control and average tumour samples (iii). E. Venn diagram displaying the level of overlap in 
promoters which both lose 5hmC and gain 5mC in three Ctnnb1 tumour samples relative to the control livers. 
The total number of hypo 5hmC/hyper 5mC promoter cores in each tumour is shown between brackets. F. 
Examples of 2 promoters which exhibit PB loss of 5hmc/ tumour gain of 5mC. All data is plotted between log2 -
1.5 to log2 +1.5.G. Heat map analysis of log2 5hmC (blue) and 5mC (red) signals over the promoter regions 
(TSS +/- 2kb) present on the array ranked by Ha-ras tumour 5mC level for average normal control livers (n=2), 
average Ctnnb1 tumours (n=3) and a Ha-ras mutated liver tumour. CGIs are denoted by black bars in the far 
right plot. Average 5hmC and 5mC patterns across all promoters are plotted below 
 
Fig. 2. Epigenetic perturbations weakly associate with changes in transcriptional state during 
hepatocarcinogenesis. A. Scatter plot analysis of change in promoter core 5hmC (i) and 5mC (ii) signal versus 
log2 fold change in expression following PB exposure or resulting tumours. Green: induced (>log2 2 fold 
elevated), red: repressed (>log2 2 fold repressed), grey: unchanged expression. Select genes are highlighted. B. 
Boxplot of change in promoter core 5hmC (i) and 5mC (ii) over the total gene set (grey), induced (green and 
repressed (pink) genes between control and tumour samples. Although typically following the global trend (i.e. 
loss of 5hmC/gain in 5mC in all three gene sets) there is significantly more 5hmC over the promoter cores of 
repressed genes and less 5mC over induced gene sets. Fisher’s P-values are shown between plots. C. Example 
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of epigenetic perturbation and transcriptional changes at the Cyp2b10 gene. 5mC and 5hmC microarray data 
plotted from log2 -1.5 to log2 +1.5. RNA-seq data plotted from RPKM of 0 to 2000. D. Average RPKM value 
across total gene set for control (C1, C2: greens), PB (PB1, PB2: blues) and tumour (T1, T2 & T3: reds).  
Fig. 3. The normal liver transcriptome is perturbed following PB exposure and in resulting tumour samples. 
A. Sets of genes which change their transcriptional activity following either PB treatment, in the PB tumours or 
in both sets of samples were stratified into one of 6 groups (i-vi) plotted as change in expression relative to the 
control liver group. Examples of select induced genes (blue) and repressed genes (red) are shown under each 
group in a dashed box. B. Plots of P-values associated with significantly enriched pathways based analysis of 
groups of genes induced (i-iii) or repressed (iv-vi) following PB treatment or in the tumour samples relative to 
control livers. No pathways were found enriched in the gene set from group vi (down PB only). C. Plots of 
RPKM values (reads per kilobase per million) over candidate genes of interest which have potential roles in cell 
signalling, cancer progression and xenobiotic response. Roman numeral above each gene is related to the 
groups identified in Fig 3A. D. Plots of change in the levels of established fetal and adult liver specific 
transcripts between control livers to those exposed to PB for 12 weeks (blue bars), to PB exposed liver 
tumours (red bars) or to fetal livers (yellow bar). Change in expression is plotted as log2 fold change vs average 
signal from the control livers. E. Fold change in expression signals for fetal and adult liver transcripts taken 
from published microarrays relative to control livers for PB exposed Ctnnb1 mutated liver tumours (red), non-
PB driven Ha-Ras mutated tumours (pink) and long term PB exposed livers without tumours (grey).  
 
Fig. 4. Polycomb signatures are perturbed in the PB exposed & Ctnnb1 mutated liver tumours. A. Distribution 
of hyper- and hypo-H3K27me3 peak windows normalised to the number of each feature. Hyper-H3K27me3 
peaks: blue bars, hypo-H3K27me3 peaks: yellow bars. Promoter distal : TSS -2kb to -1kb, promoter proximal: 
TSS -1kb to -250bp, promoter core TSS+/-250bp, Intra-genic: TSS+250bp to TES, Inter-genic: all remaining 
features  B. Box plot of promoter core H3K27me3 signals for control (grey), 12 week PB (yellow) and tumour 
(maroon) samples. C. Density scatter plot of change in promoter-core DNA modification state versus change in 
H3K27me3 signal for average 5hmC and 5mC upon PB exposure (i & iii) or in the tumour samples (ii & iv). D. 
Plots of average control and tumour H3K27me3 patterns across the total promoter cohort, promoters 
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identified as hypo-5hmC/ hyper-5mC in the tumours, promoters of tumour induced genes and promoters of 
tumour repressed genes. Control liver patterns: Black line, Tumour patterns: brown line, Control liver 
H3K27me3 pattern from total promoter set: dashed green line. Plots cover promoter regions TSS +/- 2kb. E. 
Examples of H3K27me3 ChIP-seq patterns, 5hmC & 5mC microarray patterns and RNAseq expression states at 
loci identified in Fig. 4D. F. Average patterns of several histone modifications in the control livers at the tumour 
hypo-5hmC/ hyper-5mC promoter regions. black line: patterns across the total promoter set. Plots shown for 
TSS +/-2kb regions. G. Heat map analysis of the bivalency modifications H3K27me3 and H3K4me3, DNA 
modifications and expression status over the tumour hypo-5hmC/hyper-5mC promoter-core regions. A 
random selection of 1000 promoters were tested as a comparison. H3K27me3: green, H3K4me3: purple, 5hmC 
and 5mC (blue: high, red: low), RNAseq RPKM (grey).  
 
Fig. 5. The role of Tet1 in the maintenance of epigenetic state during hepatocarcinogenesis. A. Heat-map of 
expression change (fold change in RPKM) for key epigenetic proteins following PB exposure and in tumour 
samples. Green: induced, red: repressed. B. Immunostaining of control healthy liver and two liver tumours for 
glutamine synthase (GS: hepatocytes at central vein), Mitogen-activated protein kinase (MAPK: tumour 
positive cells) and Tet1. C. Heatmap analysis of 5hmC landscape at promoters (TSS+/- 2kb) in control healthy 
liver versus those in a Tet1 deficient mouse (Tet1-/-). 5hmC levels ranked by control promoter core level. Blue = 
high, Red= low). D. Model illustrating how Tet1 may regulate the CGI epigenetic landscape in liver. Examples of 
epigenetic landscapes are shown for the promoter regions of genes transcriptionally induced or repressed 
during hepatocarcinogenesis or at the promoters of genes which exhibit aberrant promoter hypo 
hydroxymethylation/hypermethylation in the liver tumours. H3K27me3: Orange triangle, H3K4me3: green 
oval, 5hmCpG: blue lollypop, 5mCpG: black lollypop, unmodified CpG: white circle. Possible mechanisms to 
explain the role of Tet1 at CGIs are outlined (i-iv). Transcription factor (TF) binding events are also shown. For 
reference the global changes in the three epigenetic marks are shown alongside with a gain in a mark 
represented by a green arrow, a loss in the mark by a red arrow and no change by a black bar.  
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